Mode
Text Size
Log in / Sign up
Phase 3 Completed N=18 Supportive Care

Fentanyl Sublingual Spray in Treating Opioid-tolerant Cancer Patients With or Without Oral Mucositis

Mucositis · Postoperative Pain · Unspecified Adult Solid Tumor, Protocol Specific
Source: ClinicalTrials.gov NCT00956254 ↗
Enrolled (actual)
18
Serious AEs
0.0%
Results posted
Sep 2013
Primary outcomePrimary: Cmax of Fentanyl — 0.67; 0.26 ng/mL

Summary

This was an open-label, single-dose study to assess the safety, tolerability, and absorption/distribution kinetics of a single 100 µg dose of fentanyl sublingual spray in opioid-tolerant cancer subjects, with or without oral mucositis.

Outcome Measures

OutcomeResultp-value
PRIMARY
Cmax of Fentanyl
0.67; 0.26
SECONDARY
Tmax of Fentanyl
0.53; 0.56
SECONDARY
AUC0-last of Fentanyl
3.11; 0.91

Eligibility Criteria

DISEASE CHARACTERISTICS:

  • Diagnosis of cancer and meets 1 of the following criteria:
  • Mild mucositis, defined as grade 1 (erythema of the mucosa) or 2 (patchy ulcerations or pseudomembranes) on the day of study drug administration.
  • No mucositis, defined as normal oral cavity upon examination on the day of study drug administration.
  • Opioid-tolerant, defined as patients who are taking ≥ 60 mg of oral morphine/day, ≥ 30 mg of oxycodone/day, ≥ 8 mg of oral hydromorphone/day, or an equianalgesic dose of another opioid for ≥ 7 days for cancer-related pain.
  • Persistent pain related to cancer or its treatment over the past 7 days.
  • No brain metastases with signs or symptoms of increased intracranial pressure.

PATIENT CHARACTERISTICS:

  • Negative pregnancy test.
  • Agree to be confined to study site for approximately 12 hours, to eat only the food served by the study unit during the study confinement period, and to consume all food provided at the designated meal or snack times.
  • No history of major organ system impairment or disease that, in the investigator's or his/her designee's opinion, could increase the risk associated with the use of opioids.
  • No uncontrolled hypertension despite antihypertensive therapy or history of hypertensive crisis within the past 2 years.
  • No recent history (within the past 2 years) of transient ischemic attacks, neural vascular disease, stroke, or cerebral aneurysms.
  • No intolerable side effects to opioids or fentanyl.

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics.
  • More than 30 days since prior investigational agents.
  • More than 14 days since prior monoamine oxidase inhibitors.
  • No prior participation in either Insys Fentanyl Sublingual Spray Phase III study INSYS-INS-05-001 or INSYS-INS-06-007.
  • No other concurrent use of any fentanyl product.
  • Patients who have received Actiq®, Fentora®, or Duragesic® are eligible after a 7-day washout.
  • No concurrent medications (prescription, over-the-counter, vitamin, or herbal substances) except for hormonal contraceptives and/or ≤ 3 doses of acetaminophen at ≤ 1 g each.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00956254). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search